Nature Medicine | Spoonful of Medicine

Experts diverge on stock price flux ahead of cancer trial results

Posted on behalf of Madhumita Venkataramanan The stock prices of companies that report positive results for cancer drug trials tended to increase before the first public announcement of the findings, according to a study published today in the Journal of the National Cancer Institute. But experts are split as to whether the trend points to illegal ‘insider trading’ by people who know the results of these trials in advance — including physicians and scientists — or simply reflect a bias in the analysis. In the study, a team led by pharmacoeconomist Allan Detsky of Mount Sinai Hospital in Toronto identified 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.